Apollomics Inc Ordinary Shares - Class A APLM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
-
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
-
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
-
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
-
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Trading Information
- Previous Close Price
- $0.16
- Day Range
- $0.16–0.17
- 52-Week Range
- $0.11–3.20
- Bid/Ask
- $0.16 / $0.16
- Market Cap
- $17.38 Mil
- Volume/Avg
- 376,546 / 4.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 1.36
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 45
- Website
- https://www.apollomicsinc.com
Comparables
Valuation
|
Metric
|
APLM
|
06978
|
6550
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.36 | — | — |
Price/Book Value | 0.84 | — | 5.87 |
Price/Sales | — | — | 617.57 |
Price/Cash Flow | — | — | — |
Price/Earnings
APLM
06978
6550
Financial Strength
|
Metric
|
APLM
|
06978
|
6550
|
|---|---|---|---|
Quick Ratio | 2.08 | 0.36 | 9.39 |
Current Ratio | 2.25 | 0.38 | 9.86 |
Interest Coverage | −256.41 | −37.83 | −41.75 |
Quick Ratio
APLM
06978
6550
Profitability
|
Metric
|
APLM
|
06978
|
6550
|
|---|---|---|---|
Return on Assets (Normalized) | −60.79% | −24.06% | −18.61% |
Return on Equity (Normalized) | −103.83% | −267.27% | −22.52% |
Return on Invested Capital (Normalized) | −77.50% | −30.83% | −21.09% |
Return on Assets
APLM
06978
6550
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kwhzlckct | Dnzc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lzqrrxpd | Szdzm | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hyygbsyj | Ynhflv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xxggjxxn | Hpwmsx | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Wkhzqhvw | Qfxn | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fclksqfn | Wvsdj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Qqbmzrx | Tnsz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Zvhyxdrn | Kmcjf | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Drnctmhym | Zbxbmzj | $13.2 Bil | |||
| Incyte Corp
INCY
| Vgmdwvh | Pztlffn | $13.0 Bil |
United States